**Appendix Table H5. Summary risk of bias assessments: nutraceuticals in adults with MCI**

|  |  |  |  |
| --- | --- | --- | --- |
| **Nutraceutical Type** | **Study** | **Overall Risk of Bias Assessment** | **Rationale** |
| **Omega 3 fatty acids efficacy** | Lee 201321 | Low/Medium | Possible detection bias (unclear outcomes assessment) |
| **Ginkgo biloba** | Gavrilova, 201422 | Low |  |
|  | DeKosky, 200814 | Low |   |
| **Omega 3 fatty acids comparative effectiveness** | Sinn, 201223 | High | Randomization not well described; attrition > 25% without appropriate analysis to account for possible bias |

MCI=mild cognitive impairment